Engineered CRISPR Systems for Next Generation Gene Therapies

Michael Pineda, Farzaneh Moghadam, Mohammad Ebrahimkhani, Samira Kiani

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

An ideal in vivo gene therapy platform provides safe, reprogrammable, and precise strategies which modulate cell and tissue gene regulatory networks with a high temporal and spatial resolution. Clustered regularly interspaced short palindromic repeats (CRISPR), a bacterial adoptive immune system, and its CRISPR-associated protein 9 (Cas9), have gained attention for the ability to target and modify DNA sequences on demand with unprecedented flexibility and precision. The precision and programmability of Cas9 is derived from its complexation with a guide-RNA (gRNA) that is complementary to a desired genomic sequence. CRISPR systems open-up widespread applications including genetic disease modeling, functional screens, and synthetic gene regulation. The plausibility of in vivo genetic engineering using CRISPR has garnered significant traction as a next generation in vivo therapeutic. However, there are hurdles that need to be addressed before CRISPR-based strategies are fully implemented. Some key issues center on the controllability of the CRISPR platform, including minimizing genomic-off target effects and maximizing in vivo gene editing efficiency, in vivo cellular delivery, and spatial-temporal regulation. The modifiable components of CRISPR systems: Cas9 protein, gRNA, delivery platform, and the form of CRISPR system delivered (DNA, RNA, or ribonucleoprotein) have recently been engineered independently to design a better genome engineering toolbox. This review focuses on evaluating CRISPR potential as a next generation in vivo gene therapy platform and discusses bioengineering advancements that can address challenges associated with clinical translation of this emerging technology.

Original languageEnglish (US)
Pages (from-to)1614-1626
Number of pages13
JournalACS Synthetic Biology
Volume6
Issue number9
DOIs
StatePublished - Sep 15 2017

Fingerprint

Clustered Regularly Interspaced Short Palindromic Repeats
Gene therapy
Genetic Therapy
RNA
Proteins
Genes
CRISPR-Associated Proteins
Guide RNA
Genetic engineering
Immune system
DNA sequences
Open systems
Controllability
Complexation
Gene expression
DNA
Tissue
Synthetic Genes
Bioengineering
Inborn Genetic Diseases

Keywords

  • Cas9
  • clustered regularly interspaced short palindromic repeats
  • controllable CRISPR
  • CRISPR
  • gene editing
  • gene modulation,gRNA
  • gene therapy
  • safe CRISPR
  • synthetic biology

ASJC Scopus subject areas

  • Biomedical Engineering
  • Biochemistry, Genetics and Molecular Biology (miscellaneous)

Cite this

Engineered CRISPR Systems for Next Generation Gene Therapies. / Pineda, Michael; Moghadam, Farzaneh; Ebrahimkhani, Mohammad; Kiani, Samira.

In: ACS Synthetic Biology, Vol. 6, No. 9, 15.09.2017, p. 1614-1626.

Research output: Contribution to journalReview article

Pineda, Michael ; Moghadam, Farzaneh ; Ebrahimkhani, Mohammad ; Kiani, Samira. / Engineered CRISPR Systems for Next Generation Gene Therapies. In: ACS Synthetic Biology. 2017 ; Vol. 6, No. 9. pp. 1614-1626.
@article{2aa0f83752574b4fbef5f83cfe44abc7,
title = "Engineered CRISPR Systems for Next Generation Gene Therapies",
abstract = "An ideal in vivo gene therapy platform provides safe, reprogrammable, and precise strategies which modulate cell and tissue gene regulatory networks with a high temporal and spatial resolution. Clustered regularly interspaced short palindromic repeats (CRISPR), a bacterial adoptive immune system, and its CRISPR-associated protein 9 (Cas9), have gained attention for the ability to target and modify DNA sequences on demand with unprecedented flexibility and precision. The precision and programmability of Cas9 is derived from its complexation with a guide-RNA (gRNA) that is complementary to a desired genomic sequence. CRISPR systems open-up widespread applications including genetic disease modeling, functional screens, and synthetic gene regulation. The plausibility of in vivo genetic engineering using CRISPR has garnered significant traction as a next generation in vivo therapeutic. However, there are hurdles that need to be addressed before CRISPR-based strategies are fully implemented. Some key issues center on the controllability of the CRISPR platform, including minimizing genomic-off target effects and maximizing in vivo gene editing efficiency, in vivo cellular delivery, and spatial-temporal regulation. The modifiable components of CRISPR systems: Cas9 protein, gRNA, delivery platform, and the form of CRISPR system delivered (DNA, RNA, or ribonucleoprotein) have recently been engineered independently to design a better genome engineering toolbox. This review focuses on evaluating CRISPR potential as a next generation in vivo gene therapy platform and discusses bioengineering advancements that can address challenges associated with clinical translation of this emerging technology.",
keywords = "Cas9, clustered regularly interspaced short palindromic repeats, controllable CRISPR, CRISPR, gene editing, gene modulation,gRNA, gene therapy, safe CRISPR, synthetic biology",
author = "Michael Pineda and Farzaneh Moghadam and Mohammad Ebrahimkhani and Samira Kiani",
year = "2017",
month = "9",
day = "15",
doi = "10.1021/acssynbio.7b00011",
language = "English (US)",
volume = "6",
pages = "1614--1626",
journal = "ACS Synthetic Biology",
issn = "2161-5063",
publisher = "American Chemical Society",
number = "9",

}

TY - JOUR

T1 - Engineered CRISPR Systems for Next Generation Gene Therapies

AU - Pineda, Michael

AU - Moghadam, Farzaneh

AU - Ebrahimkhani, Mohammad

AU - Kiani, Samira

PY - 2017/9/15

Y1 - 2017/9/15

N2 - An ideal in vivo gene therapy platform provides safe, reprogrammable, and precise strategies which modulate cell and tissue gene regulatory networks with a high temporal and spatial resolution. Clustered regularly interspaced short palindromic repeats (CRISPR), a bacterial adoptive immune system, and its CRISPR-associated protein 9 (Cas9), have gained attention for the ability to target and modify DNA sequences on demand with unprecedented flexibility and precision. The precision and programmability of Cas9 is derived from its complexation with a guide-RNA (gRNA) that is complementary to a desired genomic sequence. CRISPR systems open-up widespread applications including genetic disease modeling, functional screens, and synthetic gene regulation. The plausibility of in vivo genetic engineering using CRISPR has garnered significant traction as a next generation in vivo therapeutic. However, there are hurdles that need to be addressed before CRISPR-based strategies are fully implemented. Some key issues center on the controllability of the CRISPR platform, including minimizing genomic-off target effects and maximizing in vivo gene editing efficiency, in vivo cellular delivery, and spatial-temporal regulation. The modifiable components of CRISPR systems: Cas9 protein, gRNA, delivery platform, and the form of CRISPR system delivered (DNA, RNA, or ribonucleoprotein) have recently been engineered independently to design a better genome engineering toolbox. This review focuses on evaluating CRISPR potential as a next generation in vivo gene therapy platform and discusses bioengineering advancements that can address challenges associated with clinical translation of this emerging technology.

AB - An ideal in vivo gene therapy platform provides safe, reprogrammable, and precise strategies which modulate cell and tissue gene regulatory networks with a high temporal and spatial resolution. Clustered regularly interspaced short palindromic repeats (CRISPR), a bacterial adoptive immune system, and its CRISPR-associated protein 9 (Cas9), have gained attention for the ability to target and modify DNA sequences on demand with unprecedented flexibility and precision. The precision and programmability of Cas9 is derived from its complexation with a guide-RNA (gRNA) that is complementary to a desired genomic sequence. CRISPR systems open-up widespread applications including genetic disease modeling, functional screens, and synthetic gene regulation. The plausibility of in vivo genetic engineering using CRISPR has garnered significant traction as a next generation in vivo therapeutic. However, there are hurdles that need to be addressed before CRISPR-based strategies are fully implemented. Some key issues center on the controllability of the CRISPR platform, including minimizing genomic-off target effects and maximizing in vivo gene editing efficiency, in vivo cellular delivery, and spatial-temporal regulation. The modifiable components of CRISPR systems: Cas9 protein, gRNA, delivery platform, and the form of CRISPR system delivered (DNA, RNA, or ribonucleoprotein) have recently been engineered independently to design a better genome engineering toolbox. This review focuses on evaluating CRISPR potential as a next generation in vivo gene therapy platform and discusses bioengineering advancements that can address challenges associated with clinical translation of this emerging technology.

KW - Cas9

KW - clustered regularly interspaced short palindromic repeats

KW - controllable CRISPR

KW - CRISPR

KW - gene editing

KW - gene modulation,gRNA

KW - gene therapy

KW - safe CRISPR

KW - synthetic biology

UR - http://www.scopus.com/inward/record.url?scp=85029489676&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029489676&partnerID=8YFLogxK

U2 - 10.1021/acssynbio.7b00011

DO - 10.1021/acssynbio.7b00011

M3 - Review article

C2 - 28558198

AN - SCOPUS:85029489676

VL - 6

SP - 1614

EP - 1626

JO - ACS Synthetic Biology

JF - ACS Synthetic Biology

SN - 2161-5063

IS - 9

ER -